Ultragenyx Pharmaceutical (RARE) Leases: 2019-2023
Historic Leases for Ultragenyx Pharmaceutical (RARE) over the last 5 years, with Sep 2023 value amounting to $26.4 million.
- Ultragenyx Pharmaceutical's Leases fell 8.08% to $26.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $26.4 million, marking a year-over-year decrease of 8.08%. This contributed to the annual value of $26.0 million for FY2022, which is 25.69% down from last year.
- As of Q3 2023, Ultragenyx Pharmaceutical's Leases stood at $26.4 million, which was up 37.48% from $19.2 million recorded in Q2 2023.
- Ultragenyx Pharmaceutical's 5-year Leases high stood at $40.5 million for Q4 2020, and its period low was $19.2 million during Q2 2023.
- Over the past 3 years, Ultragenyx Pharmaceutical's median Leases value was $31.2 million (recorded in 2022), while the average stood at $30.5 million.
- As far as peak fluctuations go, Ultragenyx Pharmaceutical's Leases surged by 55.61% in 2020, and later tumbled by 38.48% in 2023.
- Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's Leases stood at $30.3 million in 2019, then skyrocketed by 33.62% to $40.5 million in 2020, then decreased by 13.79% to $34.9 million in 2021, then declined by 25.69% to $26.0 million in 2022, then fell by 8.08% to $26.4 million in 2023.
- Its Leases was $26.4 million in Q3 2023, compared to $19.2 million in Q2 2023 and $22.9 million in Q1 2023.